Tyra Biosciences, Inc. (TYRA) Income Statement
TYRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTYRA revenue and net income
TYRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TYRA quarterly EPS vs estimates
Tyra Biosciences beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.66).
TYRA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $546,000 | $519,000 | $353,000 | $296,000 | $140,000 | $47,000 | $8,000 |
| Gross profit | −$546,000 | −$519,000 | −$353,000 | −$296,000 | −$140,000 | −$47,000 | −$8,000 |
| Research & development | $102.9M | $80.1M | $62.5M | $43.0M | $20.6M | $7.2M | $1.8M |
| Sales, general & admin | $29.8M | $24.1M | $17.4M | $15.9M | $5.7M | $2.1M | $1.3M |
| Total operating expenses | $132.8M | $104.2M | $79.9M | $58.9M | $26.3M | $9.2M | $3.1M |
| Operating income | −$132.8M | −$104.2M | −$79.9M | −$58.9M | −$26.3M | −$9.3M | −$3.1M |
| Interest income | $12.8M | $17.7M | $10.8M | $3.7M | $13,000 | — | — |
| Interest expense | — | — | — | $296,000 | $140,000 | $1,000 | $1,000 |
| Income before taxes | −$119.9M | −$86.5M | −$69.1M | −$55.3M | −$26.3M | −$9.3M | −$4.1M |
| Income taxes | — | — | — | −$3.6M | −$153,000 | −$22,000 | −$7,000 |
| Net income | −$119.9M | −$86.5M | −$69.1M | −$51.7M | −$26.1M | −$9.3M | −$4.1M |
| EBITDA | −$119.4M | −$86.0M | −$68.8M | −$58.6M | −$26.1M | −$9.2M | −$3.1M |
| EPS (diluted) | −$2.01 | −$1.51 | −$1.61 | −$1.33 | −$1.24 | −$6.97 | −$1.07 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $496,000 | $0 | $0 | $0 | $502,000 | $0 |
| Cost of revenue | — | $138,000 | $132,000 | — | $140,000 | $143,000 | $248,000 | $127,000 | $126,000 | $122,000 | $102,000 | $82,000 |
| Gross profit | — | −$138,000 | −$132,000 | — | −$140,000 | −$143,000 | $248,000 | −$127,000 | −$126,000 | −$122,000 | $400,000 | −$82,000 |
| Research & development | $39.2M | $33.3M | $28.2M | $25.5M | $24.3M | $25.0M | $22.2M | $22.7M | $17.9M | $17.1M | $20.7M | $19.3M |
| Sales, general & admin | $9.8M | $8.5M | $8.3M | $7.5M | $7.1M | $6.9M | $7.6M | $5.9M | $5.5M | $5.1M | $5.0M | $4.7M |
| Total operating expenses | $49.0M | $41.9M | $36.5M | $32.9M | $31.5M | $31.9M | $29.7M | $28.6M | $23.4M | $22.2M | $25.6M | $24.0M |
| Operating income | −$49.0M | −$42.0M | −$36.5M | −$32.9M | −$31.5M | −$31.9M | −$29.7M | −$28.6M | −$23.5M | −$22.3M | −$25.6M | −$24.0M |
| Interest income | $3.4M | $2.7M | $2.7M | $3.1M | $3.4M | $3.7M | $4.2M | $4.6M | $4.8M | $4.1M | $2.8M | $2.8M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $2.5M | $5,000 |
| Income before taxes | −$45.6M | −$39.3M | −$33.8M | −$29.9M | −$28.1M | −$28.1M | −$25.6M | −$24.0M | −$18.7M | −$18.2M | −$22.8M | −$21.2M |
| Income taxes | — | — | — | — | — | — | — | — | — | $78,724 | $8.0M | −$2.8M |
| Net income | −$45.6M | −$39.3M | −$33.8M | −$29.9M | −$28.1M | −$28.1M | −$25.6M | −$24.0M | −$18.7M | −$18.2M | −$22.8M | −$21.2M |
| EBITDA | −$45.4M | −$39.2M | −$33.7M | −$29.7M | −$28.0M | −$28.0M | −$25.4M | −$23.9M | −$18.6M | −$18.1M | −$22.7M | −$21.1M |
| EPS (diluted) | −$0.69 | −$0.64 | −$0.57 | −$0.50 | −$0.47 | −$0.47 | −$0.43 | −$0.41 | −$0.32 | −$0.35 | −$0.53 | −$0.49 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 79.7% | — |
| Operating margin | — | — | — | — | — | — | −5,996.8% | — | — | — | −5,106.4% | — |
| Net margin | — | — | — | — | — | — | −5,155.4% | — | — | — | −4,547.8% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TYRA's financial statements (latest annual report filed March 2, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TYRA financial results
Tyra Biosciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $119.9 million. Diluted earnings per share came to −$2.01.
See the TYRA stock overview for the latest quote and news, or the TYRA chart for price history and technical indicators.
TYRA income statement FAQ
Does Tyra Biosciences have revenue?
Tyra Biosciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Tyra Biosciences profitable?
No. Tyra Biosciences reported a net loss of $119.9 million in fiscal 2025.
How much does Tyra Biosciences spend on research and development?
Tyra Biosciences spent $102.9 million on research and development in fiscal 2025.
What are Tyra Biosciences's earnings per share?
Tyra Biosciences earned $-2.01 per diluted share in fiscal 2025, compared with $-1.51 a year earlier.
When will Tyra Biosciences report its next earnings?
Tyra Biosciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Tyra Biosciences's fiscal year end?
Tyra Biosciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 2, 2026.